351 related articles for article (PubMed ID: 35794583)
21. The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma.
Zou J; Zhong X; Zhou X; Xie Q; Zhao Z; Guo X; Duan Y
Biochem Biophys Res Commun; 2021 Nov; 580():48-55. PubMed ID: 34624569
[TBL] [Abstract][Full Text] [Related]
22. ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression.
An X; Wu W; Yang L; Dong J; Liu B; Guo J; Chen J; Guo B; Cao W; Jiang Q
Transl Res; 2023 Sep; 259():62-71. PubMed ID: 37121538
[TBL] [Abstract][Full Text] [Related]
23. Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma - a retrospective study using TCGA database.
Zhou J; Wang J; Hong B; Ma K; Xie H; Li L; Zhang K; Zhou B; Cai L; Gong K
Aging (Albany NY); 2019 Mar; 11(6):1633-1647. PubMed ID: 30877265
[TBL] [Abstract][Full Text] [Related]
24. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
Xu H; Wang H; Zhao W; Fu S; Li Y; Ni W; Xin Y; Li W; Yang C; Bai Y; Zhan M; Lu L
Theranostics; 2020; 10(13):5671-5686. PubMed ID: 32483411
[No Abstract] [Full Text] [Related]
25. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism.
Xie W; Ma LL; Xu YQ; Wang BH; Li SM
Biochem Biophys Res Commun; 2019 Oct; 518(1):120-126. PubMed ID: 31405565
[TBL] [Abstract][Full Text] [Related]
26. Regulation of HHLA2 expression in kidney cancer and myeloid cells.
Shigemura T; Perrot N; Huang Z; Bhatt RS; Sheshdeh AB; Ahmar NE; Ghandour F; Signoretti S; McDermott DF; Freeman GJ; Mahoney KM
BMC Cancer; 2023 Oct; 23(1):1039. PubMed ID: 37891555
[TBL] [Abstract][Full Text] [Related]
27. METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression.
Zhang Y; Liu S; Zhao T; Dang C
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34132367
[TBL] [Abstract][Full Text] [Related]
28. Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2-dependent mechanism.
Ni WJ; Zhou H; Lu H; Ma NN; Hou BB; Li W; Kong FX; Yu JT; Hou R; Jin J; Wen JG; Zhang T; Meng XM
Clin Transl Med; 2023 Aug; 13(8):e1359. PubMed ID: 37537731
[TBL] [Abstract][Full Text] [Related]
29. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
30. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.
Du Y; Hou G; Zhang H; Dou J; He J; Guo Y; Li L; Chen R; Wang Y; Deng R; Huang J; Jiang B; Xu M; Cheng J; Chen GQ; Zhao X; Yu J
Nucleic Acids Res; 2018 Jun; 46(10):5195-5208. PubMed ID: 29506078
[TBL] [Abstract][Full Text] [Related]
31. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
Wang H; Xu B; Shi J
Gene; 2020 Jan; 722():144076. PubMed ID: 31454538
[TBL] [Abstract][Full Text] [Related]
32. Alternative splicing of METTL3 explains apparently METTL3-independent m6A modifications in mRNA.
Poh HX; Mirza AH; Pickering BF; Jaffrey SR
PLoS Biol; 2022 Jul; 20(7):e3001683. PubMed ID: 35853000
[TBL] [Abstract][Full Text] [Related]
33. METTL3 facilitates renal cell carcinoma progression by PLOD2 m
Chen Y; He Y; Li Z; Zhang N; Zhou C; He X; Xue D
Cell Death Dis; 2024 Jan; 15(1):62. PubMed ID: 38233403
[TBL] [Abstract][Full Text] [Related]
34. An Alternatively Spliced Variant of METTL3 Mediates Tumor Suppression in Hepatocellular Carcinoma.
Xu RY; Ding Z; Zhao Q; Ke TY; Chen S; Wang XY; Wang YY; Sheng MF; Wang W; Long N; Shen YX; Xu YZ; Shao W
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456475
[TBL] [Abstract][Full Text] [Related]
35. METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
Zhou D; Tang W; Xu Y; Xu Y; Xu B; Fu S; Wang Y; Chen F; Chen Y; Han Y; Wang G
Mol Oncol; 2021 Aug; 15(8):2172-2184. PubMed ID: 33411363
[TBL] [Abstract][Full Text] [Related]
36. METTL3-mediated N6-methyladenosine modification of DUSP5 mRNA promotes gallbladder-cancer progression.
Chen HD; Li F; Chen S; Zhong ZH; Gao PF; Gao WZ
Cancer Gene Ther; 2022 Jul; 29(7):1012-1020. PubMed ID: 34799724
[TBL] [Abstract][Full Text] [Related]
37. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
[TBL] [Abstract][Full Text] [Related]
39. The m
Cheng M; Sheng L; Gao Q; Xiong Q; Zhang H; Wu M; Liang Y; Zhu F; Zhang Y; Zhang X; Yuan Q; Li Y
Oncogene; 2019 May; 38(19):3667-3680. PubMed ID: 30659266
[TBL] [Abstract][Full Text] [Related]
40. METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1.
Song D; Wang Q; Yan Z; Su M; Zhang H; Shi L; Fan Y; Zhang Q; Yang H; Zhang D; Liu Q
Biol Direct; 2024 Jun; 19(1):44. PubMed ID: 38849910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
